3/6
02:31 am
gh
Guardant Health Tour Highlights Colorectal Test Uptake And Valuation Gap [Yahoo! Finance]
Low
Report
Guardant Health Tour Highlights Colorectal Test Uptake And Valuation Gap [Yahoo! Finance]
3/4
07:16 am
gh
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America [Yahoo! Finance]
Low
Report
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America [Yahoo! Finance]
3/4
07:00 am
gh
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
Low
Report
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
3/3
07:12 am
gh
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened [Yahoo! Finance]
Low
Report
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened [Yahoo! Finance]
3/3
07:00 am
gh
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
Low
Report
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
3/2
04:10 am
gh
Guardant Health, Inc. (GH) Strengthens Health Technology Portfolio with MetaSight Diagnostics Acquisition [Yahoo! Finance]
Low
Report
Guardant Health, Inc. (GH) Strengthens Health Technology Portfolio with MetaSight Diagnostics Acquisition [Yahoo! Finance]
2/27
04:05 pm
gh
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/26
12:35 pm
gh
Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools [Yahoo! Finance]
Low
Report
Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools [Yahoo! Finance]
2/26
07:59 am
gh
Guardant Health (GH) Gained from Better-Than-Expected Results [Yahoo! Finance]
Medium
Report
Guardant Health (GH) Gained from Better-Than-Expected Results [Yahoo! Finance]
2/24
07:18 am
gh
Guardant Health (NASDAQ:GH) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Guardant Health (NASDAQ:GH) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
2/23
01:24 pm
gh
Guardant Health acquires MetaSight amid positive 2026 financial outlook [Yahoo! Finance]
Low
Report
Guardant Health acquires MetaSight amid positive 2026 financial outlook [Yahoo! Finance]
2/23
12:33 pm
gh
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know [Yahoo! Finance]
Low
Report
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know [Yahoo! Finance]
2/23
10:05 am
gh
Guardant Health (NASDAQ:GH) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Medium
Report
Guardant Health (NASDAQ:GH) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
2/20
04:47 pm
gh
Guardant Health (NASDAQ:GH) had its price target raised by analysts at Leerink Partners from $170.00 to $180.00. They now have an "outperform" rating on the stock.
Medium
Report
Guardant Health (NASDAQ:GH) had its price target raised by analysts at Leerink Partners from $170.00 to $180.00. They now have an "outperform" rating on the stock.
2/20
02:42 pm
gh
Guardant Health (NASDAQ:GH) had its price target raised by analysts at JPMorgan Chase & Co. from $120.00 to $130.00. They now have an "overweight" rating on the stock.
Low
Report
Guardant Health (NASDAQ:GH) had its price target raised by analysts at JPMorgan Chase & Co. from $120.00 to $130.00. They now have an "overweight" rating on the stock.
2/20
01:10 pm
gh
Guardant Health (NASDAQ:GH) had its price target raised by analysts at Wells Fargo & Company from $120.00 to $125.00. They now have an "overweight" rating on the stock.
Low
Report
Guardant Health (NASDAQ:GH) had its price target raised by analysts at Wells Fargo & Company from $120.00 to $125.00. They now have an "overweight" rating on the stock.
2/20
10:58 am
gh
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at TD Cowen.
Medium
Report
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/20
10:57 am
gh
Guardant Health (NASDAQ:GH) was given a new $110.00 price target on by analysts at Evercore Inc.
Medium
Report
Guardant Health (NASDAQ:GH) was given a new $110.00 price target on by analysts at Evercore Inc.
2/20
09:13 am
gh
Guardant Health (NASDAQ:GH) was given a new $130.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Guardant Health (NASDAQ:GH) was given a new $130.00 price target on by analysts at Stifel Nicolaus.
2/20
08:03 am
gh
Guardant Health (NASDAQ:GH) had its price target raised by analysts at BTIG Research from $140.00 to $145.00. They now have a "buy" rating on the stock.
Medium
Report
Guardant Health (NASDAQ:GH) had its price target raised by analysts at BTIG Research from $140.00 to $145.00. They now have a "buy" rating on the stock.
2/20
08:00 am
gh
Guardant Health (NASDAQ:GH) had its price target raised by analysts at Canaccord Genuity Group Inc. from $125.00 to $135.00. They now have a "buy" rating on the stock.
Medium
Report
Guardant Health (NASDAQ:GH) had its price target raised by analysts at Canaccord Genuity Group Inc. from $125.00 to $135.00. They now have a "buy" rating on the stock.
2/20
07:18 am
gh
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/20
06:07 am
gh
Guardant Health (NASDAQ:GH) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Guardant Health (NASDAQ:GH) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
2/20
12:16 am
gh
Guardant Health Inc (GH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
Medium
Report
Guardant Health Inc (GH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
2/19
09:19 pm
gh
Guardant Health Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Guardant Health Q4 Earnings Call Highlights [Yahoo! Finance]